Lymphoma & Plasma Cell Disorders
News
ASCO, CCO issue multiple myeloma treatment guidelines
An expert panel convened by ASCO and Cancer Care Ontario reviewed 124 recent studies to develop nearly 50 specific recommendations in transplant-...
Conference Coverage
UNITY-NHL: Interim findings show activity, tolerability of umbralisib for R/R MZL
ATLANTA – The phosphoinositide 3-kinase delta inhibitor is active as a single-agent therapy in patients with relapsed or refractory marginal zone...
Conference Coverage
FDA panel calls for changes to breast implant rupture screening
The advisory panel seemed the current implant screening recommendation using MRI “useless.” They urged the adoption of ultrasound as a more...
Conference Coverage
FDA panel leans toward more robust breast implant surveillance
SILVER SPRING, MD. – Amid concern over two breast implant complications – anaplastic large cell lymphoma and autoimmune symptoms – an FDA panel...
News
MCL survival rates improve with novel agents
Median overall survival for mantle cell patients was between 52 and 57 months in two cancer registries. The researchers pointed to the impact of...
News
Worse survival seen among black patients with MCL
There was a survival gap between black and white patients, even though black patients with mantle cell lymphoma were more likely to be treated in...
News
Oral triplet deemed effective in relapsed/refractory myeloma
Combination clarithromycin, pomalidomide, and dexamethasone may be a treatment option for patients with relapsed or refractory multiple myeloma....
News
Myeloma risk score has treatment-planning potential
The score could be used to modify doses prior to treatment of transplant-ineligible patients with newly diagnosed multiple myeloma.
Conference Coverage
Myeloma therapies raise cardiovascular risks
WASHINGTON – The proteasome inhibitor carfilzomib increases risk for heart failure, and thalidomide analogs increase the risk for venous...
News
Selinexor hits FDA stumbling block
The Oncologic Drugs Advisory Committee expressed concern about the high rate of serious adverse events with the drug being developed to treat...
